Liraglutide
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Liraglutide and local guidelines before prescribing.
GLP-1 receptor agonist
Mechanism
GLP-1 receptor agonist.
Uses
Type 2 diabetes, obesity.
Dosing
- Liraglutide daily: 0.6 mg, then 1.2–1.8 mg.
Endocrinology: Diabetes - Liraglutide / dulaglutide Type 2 | Liraglutide 0.6 mg daily, then 1.2–1.8 mg. Dulaglutide 0.75–1.5 mg weekly (higher doses available).
Endocrinology: Diabetes - Liraglutide 3 mg Obesity | Daily SC; NICE TA664; stop if less than 5% loss at 12 weeks on full dose.
Endocrinology: Lipids and obesity
Side effects
Nausea, vomiting, diarrhoea, pancreatitis, gallstones, raised heart rate.
Interactions
Slows absorption of oral drugs; insulin and sulfonylureas hypoglycaemia.
Contraindications and cautions
Pancreatitis history
Monitoring
HbA1c, weight
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Avoid in severe renal or hepatic impairment
Overdose and reversal
Supportive
Special advice
Daily injection; titrate slowly.
More from the textbook: uses, cautions and other points
- Uses - type 2 diabetes (especially with obesity or cardiovascular disease - reduce cardiovascular events); weight management (semaglutide, liraglutide - NICE TAs, specialist weight services).
Endocrine: Anatomy Physiology and Pharmacology - Semaglutide, liraglutide and dulaglutide reduce cardiovascular events in people with cardiovascular disease.
Endocrinology: Diabetes
Where it is discussed in the book
- Endocrine: Anatomy Physiology and Pharmacology (1 mention)
- Endocrinology: Diabetes (3 mentions)
- Endocrinology: Lipids and obesity (1 mention)